Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: J Neuropathol Exp Neurol. 2011 Jan;70(1):36–50. doi: 10.1097/NEN.0b013e318202bfa1

Figure 3.

Figure 3

Co-immunoprecipitation (IP) of DYRK1A and alternative splicing factor (ASF) from nuclear extracts of control (Con) and Down syndrome (DS) subjects. Aliquots of nuclear extracts were immunoprecipitated with mAb 8D9 for DYRK1A and with mAb SF2/ASF for ASF. The presence of both target proteins was confirmed in Western blots (WB). DYRK1A was not detected in ASF precipitates (upper panel) and ASF was not detected in DYRK1A precipitates (bottom panel). Ten μg of the nuclear fraction of control and DS subjects were loaded in each lane.